Gemici Cengiz, Yaprak Gokhan, Batirel Hasan Fevzi, Ilhan Mahmut, Mayadagli Alpaslan
Department of Radiation Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Cevizli, Istanbul, Turkey.
Department of Thoracic Surgery, Marmara University Medical Faculty, Istanbul, Turkey.
World J Surg Oncol. 2016 Oct 13;14(1):263. doi: 10.1186/s12957-016-1024-0.
Locoregional recurrence is a major problem in esophageal cancer patients treated with definitive concomitant chemoradiotherapy. Approximately half of the patients fail locoregionally. We analyzed the impact of enlarged radiation field size and higher radiation dose incorporated to chemoradiotherapy on oncologic outcome.
Seventy-four consecutive patients with histologically proven nonmetastatic squamous or adenocarcinoma of the esophagus were included in this retrospective analysis. All patients were locally advanced cT3-T4 and/or cN0-1. Treatment consisted of either definitive concomitant chemoradiotherapy (Def-CRT) (n = 49, 66 %) or preoperative concomitant chemoradiotherapy (Pre-CRT) followed by surgical resection (n = 25, 34 %). Patients were treated with longer radiation fields. Clinical target volume (CTV) was obtained by giving 8-10 cm margins to the craniocaudal borders of gross tumor volume (GTV) instead of 4-5 cm globally accepted margins, and some patients in Def-CRT group received radiation doses higher than 50 Gy.
Isolated locoregional recurrences were observed in 9 out of 49 patients (18 %) in the Def-CRT group and in 1 out of 25 patients (3.8 %) in the Pre-CRT group (p = 0.15). The 5-year survival rate was 59 % in the Def-CRT group and 50 % in the Pre-CRT group (p = 0.72). Radiation dose was important in the Def-CRT group. Patients treated with >50 Gy (11 out of 49 patients) had better survival with respect to patients treated with 50 Gy (38 out of 49 patients). Five-year survivals were 91 and 50 %, respectively (p = 0.013).
Radiation treatment planning by enlarged radiation fields in esophageal cancer decreases locoregional recurrences considerably with respect to the results reported in the literature by standard radiation fields (18 vs >50 %). Radiation dose is as important as radiation field size; patients in the Def-CRT group treated with ≥50 Gy had better survival in comparison to patients treated with 50 Gy.
局部区域复发是接受根治性同步放化疗的食管癌患者面临的主要问题。约半数患者出现局部区域治疗失败。我们分析了扩大放疗野大小及增加同步放化疗中的放疗剂量对肿瘤学结局的影响。
本回顾性分析纳入了74例经组织学证实为非转移性食管鳞状癌或腺癌的连续患者。所有患者均为局部晚期cT3 - T4和/或cN0 - 1。治疗方案包括根治性同步放化疗(Def - CRT)(n = 49,66%)或术前同步放化疗(Pre - CRT)后行手术切除(n = 25,34%)。患者接受更大范围的放疗野。临床靶体积(CTV)通过在大体肿瘤体积(GTV)的头足边界给予8 - 10 cm的边界确定,而非全球普遍接受的4 - 5 cm边界,Def - CRT组的部分患者接受了高于50 Gy的放疗剂量。
Def - CRT组49例患者中有9例(18%)出现孤立性局部区域复发,Pre - CRT组25例患者中有1例(3.8%)出现孤立性局部区域复发(p = 0.15)。Def - CRT组的5年生存率为59%,Pre - CRT组为50%(p = 0.72)。放疗剂量在Def - CRT组中很重要。接受>50 Gy放疗的患者(49例患者中的11例)相较于接受50 Gy放疗的患者(49例患者中的38例)生存情况更好。5年生存率分别为91%和50%(p = 0.013)。
与文献报道的标准放疗野结果相比,食管癌扩大放疗野的放射治疗计划可显著降低局部区域复发率(18%对>50%)。放疗剂量与放疗野大小同样重要;Def - CRT组中接受≥50 Gy放疗的患者相较于接受50 Gy放疗的患者生存情况更好。